Mortality due to visceral leishmaniasis: Clinical and laboratory characteristics;Mortalidade por leishmaniose visceral: Aspectos clínicos e laboratoriais

Revista da Sociedade Brasileira de Medicina Tropical

Volumn 43, Issue 2, 2010, Pages 188-193

  de Oliveira, Janaina Michelle ^a   Fernandes, Ana Claudia ^a   Dorval, Maria Elizabeth Cavalheiros ^a   Alves, Túlia Peixoto ^a   Fernandes, Thiago Dias ^a   Oshiro, Elisa Teruya ^a   de Oliveira, Ana Lúcia Lyrio ^a  

^a FEDERAL UNIVERSITY OF MATO GROSSO DO SUL   (Brazil)

Author keywords

Mato grosso do sul; Mortality; Visceral leishmaniasis

Indexed keywords

ANTILEISHMANIAL AGENT; ANTIMONATE; UNCLASSIFIED DRUG;

ADULT; ALCOHOLISM; ARTICLE; BACTERIAL INFECTION; BRAZIL; CAUSE OF DEATH; CLINICAL FEATURE; COMORBIDITY; DISEASE DURATION; FEMALE; FEVER; HOSPITALIZATION; HUMAN; LABORATORY TEST; LENGTH OF STAY; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; MORTALITY; SYMPTOM; UNSPECIFIED SIDE EFFECT; VISCERAL LEISHMANIASIS;

BACTERIA (MICROORGANISMS);

EID: 77954009965     PISSN: 00378682     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0037-86822010000200016     Document Type: Article

References (50)

1. Maia-Elkhoury AN, Alves WA, Sousa-Gomes ML, Sena JM, Luna EA. Visceral leishmaniasis in Brazil: trends and challenges. Cad Saude Publica 2008; 24:2941-2947.
2. Schriefer A, Barral A, Carvalho EM, Barral-Netto M. Serum soluble markers in the evaluation of treatment in human visceral leishmaniasis. Clin Exp Immunol 1995; 102:535-540.
3. Dantas-Torres F, Brandão-Fillho SP. Visceral leishmaniasis in Brazil: revisiting paradigms of epidemiology and control. Rev Inst Med Trop Sao Paulo 2006; 48:151-156.
4. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 2004; 27:305-318.
5. Pastorino AC, Jacob CMA, Oselka GW, Carneiro-Sampaio MMS. Leishmaniose visceral: aspectos clínicos e laboratoriais. J Pediatr 2002; 78:120-127.
6. Pedrosa CMS, Rocha EMM. Aspectos clínicos e epidemiológicos da leishmaniose visceral em menores de 15 anos procedentes de Alagoas, Brasil. Rev Soc Bras Med Trop 2004; 37:300-304.
7. Kafetzis DA. An overview of paediatric leishmaniasis. J Postgrad Med 2003; 49:31-38.
8. Werneck GL, Batista MS, Gomes JR, Costa DL, Costa CH. Prognostic factors for death from visceral leishmaniasis in Teresina, Brazil. Infection 2003; 31:174-177.
9. Governo do Estado do Mato Grosso do Sul. Casos Absolutos de Leishmaniose Visceral Americana, Mato Grosso do Sul, 1999-2009 [Internet]. Mato Grosso do Sul (MS): Secretaria de Estado de Saúde. Serviço de Vigilância Epidemiológica. Relatório de Notificações de LV. SINAN; 23 dez 2009 [30 jan 2010]. Disponível em: .
10. Oliveira ALL, Paniago AMM, Dorval MEC, Leal CR, Sanches M, Cunha RV, et al. Foco emergente de leishmaniose visceral em Mato Grosso do Sul. Rev Soc Bras Med Trop 2006; 39:446-450.
11. Raw I, Cruz O, Schmidt BJ, Diament AJ, Fava-Netto C. Valores de laboratório: referências normais e patológicas sua importância clínica e terapêutica. Rio de Janeiro: Atheneu; 1989.
12. Deane LM. Leishmaniose Visceral no Brasil: estudos sobre reservatórios e transmissores realizados no Estado do Ceará. Rio de Janeiro: Serviço Nacional de Educação Sanitária; 1956.
13. Luz KG, Cabral ALLV, Fiúza VOP, Rabello AA. Urbanização das leishmanioses e a baixa resolutividade diagnóstica em municípios da região metropolitana de Belo Horizonte. Rev Soc Bras Med Trop 2001; 34:249-254.
14. Monteiro EM, Silva JCF, Costa RT, Costa DC, Barata RA, Paula EV, et al. Leishmaniose visceral: estudo de flebotomíneos e infecção canina em Montes Claros, Minas Gerais. Rev Soc Bras Med Trop 2005; 38:147-152.
15. Silva EA, Andreotti R, Honer MR. Comportamento de Lutzomyia longipalpis, vetor principal da leishmaniose visceral americana, em Campo Grande, Estado do Mato Grosso do Sul. Rev Soc Bras Med Trop 2007; 40:420-425.
16. Souza RG, Santos JF, Rodrigues HG, Aversi-Ferreira TA. Casos de leishmaniose visceral registrados no município de Montes Claros, Estado de Minas Gerais. Acta Sci Health Sci 2008; 30:155-159.
17. Oliveira ALL, Paniago AMM, Sanches MA, Dorval ME, Oshiro ET, Leal CR, et al. Asymptomatic infection in family contacts of patients with human visceral leishmaniasis in Três Lagoas, Mato Grosso do Sul State, Brazil. Cad Saúde Pública 2008; 24:2827-2833.
18. Costa CHN, Pereira HF, Araújo MV. Epidemia de leishmaniose visceral no Estado do Piauí, Brasil, 1980-1986. Rev Saude Publica 1990; 24:361-372.
19. Collin S, Davidson R, Ritmeijer K, Keus K, Melaku Y, Kipngetich S, et al. Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan. Clin Infect Dis 2004; 38:612-619.
20. Queiroz MJA, Alves JGB, Correia JB. Leishmaniose visceral: características clínico- epidemiológicas em crianças de área endêmica. J Pediatr 2004; 80:141-146.
21. Collin SM, Coleman PG, Ritmeijer K, Davidson RN. Unseen Kala-azar deaths in south Sudan (1999-2002). Trop Med Int Health 2006; 11:509-512.
22. Badaró R, Jones TC, Carvalho EM, Sampaio D, Reed SG, Barral A, et al. New perspectives on a subclinical form of visceral leishmaniasis. J Infect Dis 1986; 154:1003-1011.
23. Seaman J, Mercer AJ, Sondorp HE, Herwaldt BL. Epidemic visceral leishmaniasis in southern Sudan: treatment of severely debilitated patients under wartime conditions and with limited resources. Ann Intern Med 1996; 124:664-672.
24. Cascio A, Colomba C, Antinori S, Orobello M, Paterson D, Titone L. Pediatric visceral leishmaniasis in Western Sicily, Italy: a retrospective analysis of 111 cases. Eur J Clin Microbiol Infect Dis 2002; 21:277-282.
25. Maltezou HC, Siafas C, Mavrikou M, Spyridis P, Stavrinadis C, Karpathios TH, et al. Visceral Leishmaniasis during childhood in Southern Greece. Clin Infect Dis 2000; 31:1139-1143.
26. Barati M, Sharifi I, Daie-Parizi M, Fasihi-Harandi M. Bacterial infections in children with visceral leishmaniasis: observations made in Kerman province, southern Iran, between 1997 and 2007. Ann Trop Med Parasitol 2008; 102:635-641.
27. Kadivar MR, Kajbaf TZ, Karimi A, Alborzi A. Childhood visceral leishmaniasis complicated by bacterial infections. East Mediterr Health J 2000; 6:879-883.
28. Jerônimo SMB, Oliveira RM, Mackay S, Costa RM, Sweet J, Nascimento ET, et al. An urban outbreak of visceral leishmaniasis in Natal, Brazil. Trans R Soc Trop Med Hyg 1994; 88:386-388.
29. Kopke LFF, Café MEM, Neves LB, Scherrer MAR, Pinto-Machado J, Souza MSLA, et al. Morte após uso de antimonial pentavalente em leishmaniose tegumentar americana. An Bras Dermatol 1993; 68:259-261.
30. Ikeda FA, Laurenti MD, Cobertt CE, Feitosa MM, Machado GF, Perri SHV. Histological and immunohistochemical study of the central nervous system of dogs naturally infected by Leishmania (Leishmania) chagasi. Braz J Vet Res Anim Sci 2007; 44:5-11.
31. Meleney HE. The histopathology of kala-azar in the hamster, monkey, and man. Am J Path 1924; 1:147-174.
32. Prasad LSN, Sen S. Migration of Leishmania donovani amastigotes in cerebrospinal fluid. Am J Trop Med Hyg 1996; 55: 652-654.
33. Gasser RA Jr, Magill AJ, Oster CN, Franke ED, Grögl M, Berman JD. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Clin Infect Dis 1994; 18:83-90.
34. Santos J, Rivero A, Márquez M. Acute pancreatitis with a fatal evolution due to antimonials in patients with visceral leishmaniasis and HIV infection. An Med Interna 2000; 17:562-563.
35. Caravaca F, Munõz A, Pizarro JL, Santamaría JS, Fernadez-Alonso J. Acute renal failure in visceral leishmaniasis. Am J Nephrol 1991; 11:350-352.
36. Daher EF, Evangelista LF, Silva Júnior GB, Lima RSA, Aragão EB, Arruda GAJC, et al. Clinical presentation and renal evaluation of human visceral leishmaniasis (Kala-azar): A retrospective study of 57 patients in Brazil. Braz J Infect Dis 2008; 12:329-332.
37. Dutra M, Martinelli R, De Carvalho EM, Rodrigues LE, Brito E, Rocha H. Renal involvement in visceral leishmaniasis. Am J Kidney Dis 1985; 6:22-27.
38. Prasad LSN, Sen S, Ganguly SK. Renal involvement in Kala-azar. Indian J Med Res 1991; 95:43-46.
39. Salgado-Filho N, Ferreira TMAF, Costa JML. Envolvimento da função renal em pacientes com leishmaniose visceral (calazar). Rev Soc Bras Med Trop 2003; 36:217-221.
40. Rey LC, Martins CV, Ribeiro HB, Lima AAM. Leishmaniose visceral americana (calazar) em crianças hospitalizadas de área endêmica. J Pediatr 2005; 81:73-78.
41. Gershwin ME, Lentz DR, Beach RS, Hurley LS. Nutritional factors and autoimmunity. IV. Dietary vitamin-A deprivation induces a selective increase in IgM autoantibodies and hypergammaglobulinemia in New-Zealand black mice. J Immunol 1984; 133:222-226.
42. Chandra RK. Nutrition and immunoregulation - significance for host resistance totumors and infectious diseases in humans and rodents. J Nutr 1992; 122:754-757.
43. Fock RA, Vinolo MA, Rocha VMS, Rocha LCS, Borelli P. Protein-energy malnutrition decreases the expression of TLR-4/MD-2 and CD14 receptors in peritoneal macrophages and reduces the synthesis of TNF-á in response to lipopolysaccharide (LPS) in mice. Cytokine 2007; 40:105-114.
44. Maia TMC, Vasconcelos PRL, Fauth S, Neto RM. Hiperinfestação por Strongyloides stercoralis. RBPS 2006; 19:118-121.
45. Oliveira LCM, Ribeiro CT, Mendes DM, Oliveira TC, Costa-Cruz JM. Frequency of Strongyloides stercoralis infection in alcoholics. Mem Inst Oswaldo Cruz 2002; 97:119-121.
46. Chaisson RE, Gallant JE, Keruly JC, Moore RD. Impact of opportunistic disease on survival in patients with HIV infection. AIDS 1998; 12: 29-33.
47. Choi CM, Lerner EA. Leishmaniasis as an emerging infection. J Investig Dermatol Symp Proc 2001; 6:175-182.
48. Cruz I, Nieto J, Moreno J, Cañavate C, Desjeux P, Alvar J. Leishmania/HIV co- infections in the second decade. Indian J Med Res 2006; 123:357-388.
49. Wolday D, Akuffo H, Fessahaye G, Valantine A, Britton S. Live and killed human immunodeficiency virus type-1 increases the intracellular growth of Leishmania donovani in monocyte-derived cells. Scand J Infect Dis 1998; 30:29-34.
50. Santos MA, Marques RC, Farias CA, Vasconcelos DM, Stewart JM, Costa CHN. Predictors of an unsatisfactory response to pentavalent antimony in the treatment of American visceral leishmaniasis. Rev Soc Bras Med Trop 2002; 35:629-633.